Treprostinil
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil was approved for use in the United States in May 2002.
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil was approved for use in the United States in May 2002.
History
In 1976, the first paper on prostacyclin was published. Treprostinil (Remodulin) was approved for medical use in the United States in May 2002, and again in July 2018. Treprostinil (Tyvaso), as inhalation solution, was approved for medical use in the United States in July 2009, and again in April 2021. Treprostinil (Orenitram), as extended release tablets, was approved for medical use in the United States in December 2013. Treprostinil (Trepulmix) was authorized for medical use in the European Union in April 2020.
Trepulmix is a hybrid medicine that is similar to the reference medicine Remodulin. It contains the same active substance, but it is used for treating a different form of pulmonary hypertension. Treprostinil (Tyvaso DPI), as inhalation powder, was approved for medical use in the United States in May 2022. Treprostinil (Yutrepia), as inhalation powder, was approved for medical use in the United States in June 2025.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329070006 under CC BY-SA 4.0; modifications have been made.